Immuno-Oncology | Specialty

Expert Provides Perspective on Immunotherapy Advances in Lung Cancer

March 27th 2017

Jared Weiss, MD, offers his expert insight into the actual impact of the immunotherapy advances in lung cancer.

Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma

March 25th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Nivolumab Recommended for EU Approval in Head and Neck Cancer

March 24th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.

Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer

March 24th 2017

Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.

Dr. Thompson on the Future of Treatment in Multiple Myeloma

March 24th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Dr. Seiwert on Advice With Immunotherapy for Head and Neck Cancer

March 23rd 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

FDA Approves Avelumab for Merkel Cell Carcinoma

March 23rd 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy.

Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma

March 23rd 2017

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Expert Discusses State of Immunotherapy in Prostate Cancer

March 23rd 2017

Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.

Positive Immunotherapy Signals in TNBC Need Further Study

March 23rd 2017

Immune checkpoint inhibitors in triple-negative breast cancer are showing promise, but there must be future research to determine whether these agents can make a difference in this challenging malignancy.

PD-1 and IDO Inhibitor Combo Slated to Change Practice in Melanoma

March 23rd 2017

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.

Dr. Slovin on the Role of Immunotherapy for Prostate Cancer

March 22nd 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Dr. Vokes on Biomarker Selection in Head and Neck Cancer

March 22nd 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Expert Anticipates Exciting Advances in Adjuvant Melanoma

March 21st 2017

Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.

Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma

March 21st 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Evidence Builds for Targeting PD-1/PD-L1 Pathway in Bladder Cancer

March 21st 2017

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.

Dr. Luke on Adjuvant Therapies in Development for Melanoma

March 20th 2017

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.

Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

March 20th 2017

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Expert Examines Clues to Deploying Immunotherapy in Breast Cancer

March 18th 2017

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.